Last updated on May 2018

Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Patients With Recurrent / Refractory Multiple Myeloma | Patients With Recurrent or Refractory Multiple Myeloma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Relapsed/refractory multiple myeloma
  • Aged 18 years or more with no upper age limit
  • Have signed an informed consent

Exclusion Criteria:

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.